Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report) - Stock analysts at HC Wainwright cut their FY2026 earnings per share estimates for shares of Immix Biopharma in a research report issued to clients and investors on Monday, November 16th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.73) per share for the year, down from their previous estimate of ($0.72). HC Wainwright has a "Buy" rating and a $27.00 price objective on the stock. The consensus estimate for Immix Biopharma's current full-year earnings is ($0.75) per share. HC Wainwright also issued estimates for Immix Biopharma's Q4 2026 earnings at ($0.18) EPS, Q1 2027 earnings at ($0.19) EPS, Q2 2027 earnings at ($0.21) EPS, Q3 2027 earnings at ($0.22) EPS, Q4 2027 earnings at ($0.24) EPS and FY2027 earnings at ($0.86) EPS.
Several other equities research analysts have also recently weighed in on the stock. Citigroup restated a "market outperform" rating on shares of Immix Biopharma in a research report on Wednesday, September 30th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Immix Biopharma in a research report on Thursday, October 15th. Morgan Stanley reissued an "overweight" rating on shares of Immix Biopharma in a research note on Tuesday, October 20th. Mizuho set a $23.00 price target on shares of Immix Biopharma in a report on Thursday, October 29th. Finally, Needham & Company LLC boosted their price objective on shares of Immix Biopharma from $21.00 to $30.00 and gave the stock a "buy" rating in a research report on Tuesday, September 29th. Eight investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Immix Biopharma currently has an average rating of "Moderate Buy" and a consensus target price of $24.14.
Check Out Our Latest Stock Analysis on Immix Biopharma
Immix Biopharma Stock Down 3.7%
Immix Biopharma stock opened at $7.20 on Wednesday. The stock has a 50-day simple moving average of $9.57 and a 200 day simple moving average of $9.60. The stock has a market capitalization of $603.43 million, a price-to-earnings ratio of -8.67 and a beta of 0.29. Immix Biopharma has a 12-month low of $3.78 and a 12-month high of $15.10.
Immix Biopharma (NASDAQ:IMMX - Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.19) EPS for the quarter, hitting the consensus estimate of ($0.19).
Institutional Trading of Immix Biopharma
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Jupiter Topco LLC bought a new position in Immix Biopharma in the second quarter valued at approximately $100,816,000. Janus Henderson Group PLC raised its position in shares of Immix Biopharma by 22.5% during the 1st quarter. Janus Henderson Group PLC now owns 4,802,002 shares of the company's stock valued at $43,698,000 after acquiring an additional 880,434 shares during the last quarter. BlackRock Inc. bought a new stake in shares of Immix Biopharma during the 2nd quarter valued at $30,827,000. Opaleye Management Inc. bought a new stake in shares of Immix Biopharma during the 2nd quarter valued at $24,177,000. Finally, Marshall Wace LLP lifted its stake in shares of Immix Biopharma by 3.3% in the 3rd quarter. Marshall Wace LLP now owns 1,854,215 shares of the company's stock valued at $19,284,000 after purchasing an additional 59,307 shares during the period. 11.26% of the stock is owned by institutional investors.
Immix Biopharma Company Profile
(
Get Free Report)
Immix Biopharma is a clinical-stage biopharmaceutical company developing cell therapies for serious diseases, with a focus on relapsed or refractory AL amyloidosis, a rare condition in which abnormal proteins build up in organs and tissues. The company's lead candidate, NXC-201, is an investigational CAR T-cell therapy designed to target BCMA, a protein found on certain plasma cells. It is being studied in clinical trials and has not been approved for commercial use. Immix Biopharma is based in the United States and is led by Chief Executive Officer Ilya Rachman.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Immix Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immix Biopharma wasn't on the list.
While Immix Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.